Premium
Combination chemotherapy of advanced lymphocytic lymphoma: Importance of histologic classification in evaluating response
Author(s) -
Skarin Arthur T.,
Pinkus Geraldine S.,
Myerowitz Richard L.,
Bishop Yvonne M.,
Moloney William C.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197410)34:4<1023::aid-cncr2820340410>3.0.co;2-7
Subject(s) - medicine , vincristine , prednisone , cyclophosphamide , lymphoma , chemotherapy , gastroenterology , surgery
Thirty‐three patients with advanced lymphocytic lymphoma were treated with cyclophosphamide, vincristine, and prednisone (COP) administered in six weekly courses separated by 4‐week intervals for a total of six cycles. Thirteen patients (39%) achieved a complete remission (CR), and of these, 6 remain free of disease for 13–35 months. The median duration of CR is 19 months, compared to 5 months for partial responders (PR). Median survival for CR will exceed 31 months, compared to 10 months for PR and 2 months for nonresponders. Patients with nodular lymphocytic lymphoma (NL) had a significantly higher CR (77% or 10/13) and median survival (31 months) compared to those with diffuse lymphocytic lymphoma (DL) (12% CR or 2/17 with 7 months median survival). Eight of 13 patients (62%) with NL are alive for periods of 13–38 months. While more females had NL, the improved prognosis was related primarily to nodularity. COP as given in this study is useful in NL, but in DL alternate protocols are needed, especially in young adults who frequently develop superior vena cava syndrome, leukemia, and leukemic meningitis.